Details of the Drug Combination

General Information of Drug Combination (ID: DCJHDKD)

Drug Combination Name
BIO-300 SY-1425
Indication
Disease Entry Status REF
Melanoma Investigative [1]
Component Drugs BIO-300   DMJ7NVI SY-1425   DMH8UF0
N.A. N.A.
High-throughput Screening Result Testing Cell Line: MALME-3M
Zero Interaction Potency (ZIP) Score: 0.98
Bliss Independence Score: 3.11
Loewe Additivity Score: 8.41
LHighest Single Agent (HSA) Score: 10.24

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Rheumatoid arthritis FA20 Phase 1 [3]
Indication(s) of SY-1425
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [4]
Myelodysplastic syndrome 2A37 Phase 1 [4]
SY-1425 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Retinoic acid receptor alpha (RARA) TTW38KT RARA_HUMAN Agonist [4]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)